Topic: antibody-drug conjugates
Celldex culled another two R&D projects after its midstage failure in April, and now says it will focus its efforts mainly on two cancer antibodies.
AbbVie has terminated an early-stage trial of an antibody-drug conjugate for solid tumors.
ADC Therapeutics has dropped a midpipeline candidate for HER2-positive cancers because of toxicity issues in a phase 1 trial in solid tumors.
AstraZeneca is seeking approval of moxetumomab pasudotox in HCL patients who have undergone at least two prior lines of treatment.
Pfizer is backing out of its $635 million armed antibody tech deal with CytomX.
Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets.
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.
Daiichi Sankyo has teamed up with Glycotope to develop an antibody-drug conjugate with potential in ovarian, lung and breast cancers.
The antibody-drug conjugate specialist will use the money to take its two lead hematological cancer assets through registrational trials.
AbbVie joins forces with Bristol-Myers Squibb once again to test an experimental cancer drug with BMS' checkpoint inhibitor Opdivo.